196 related articles for article (PubMed ID: 30457486)
1. A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules.
Hammer MM; Palazzo LL; Eckel AL; Barbosa EM; Kong CY
Radiology; 2019 Feb; 290(2):506-513. PubMed ID: 30457486
[TBL] [Abstract][Full Text] [Related]
2. Cancer Risk in Subsolid Nodules in the National Lung Screening Trial.
Hammer MM; Palazzo LL; Kong CY; Hunsaker AR
Radiology; 2019 Nov; 293(2):441-448. PubMed ID: 31526256
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening.
Hammer MM; Eckel AL; Palazzo LL; Kong CY
Radiology; 2021 Sep; 300(3):586-593. PubMed ID: 34128723
[TBL] [Abstract][Full Text] [Related]
4. Lung-RADS Category 4X: Does It Improve Prediction of Malignancy in Subsolid Nodules?
Chung K; Jacobs C; Scholten ET; Goo JM; Prosch H; Sverzellati N; Ciompi F; Mets OM; Gerke PK; Prokop M; van Ginneken B; Schaefer-Prokop CM
Radiology; 2017 Jul; 284(1):264-271. PubMed ID: 28339311
[TBL] [Abstract][Full Text] [Related]
5. Lung-RADS Version 1.0 versus Lung-RADS Version 1.1: Comparison of Categories Using Nodules from the National Lung Screening Trial.
Kastner J; Hossain R; Jeudy J; Dako F; Mehta V; Dalal S; Dharaiya E; White C
Radiology; 2021 Jul; 300(1):199-206. PubMed ID: 33944631
[TBL] [Abstract][Full Text] [Related]
6. Malignancy estimation of Lung-RADS criteria for subsolid nodules on CT: accuracy of low and high risk spectrum when using NLST nodules.
Chung K; Jacobs C; Scholten ET; Mets OM; Dekker I; Prokop M; van Ginneken B; Schaefer-Prokop CM
Eur Radiol; 2017 Nov; 27(11):4672-4679. PubMed ID: 28439653
[TBL] [Abstract][Full Text] [Related]
7. Vancouver Risk Calculator Compared with ACR Lung-RADS in Predicting Malignancy: Analysis of the National Lung Screening Trial.
White CS; Dharaiya E; Dalal S; Chen R; Haramati LB
Radiology; 2019 Apr; 291(1):205-211. PubMed ID: 30667335
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients.
Hammer MM; Palazzo LL; Paquette A; Eckel AL; Jacobson FL; Barbosa EM; Kong CY
J Thorac Oncol; 2020 Aug; 15(8):1298-1305. PubMed ID: 32171847
[TBL] [Abstract][Full Text] [Related]
9. Volume and mass doubling times of persistent pulmonary subsolid nodules detected in patients without known malignancy.
Song YS; Park CM; Park SJ; Lee SM; Jeon YK; Goo JM
Radiology; 2014 Oct; 273(1):276-84. PubMed ID: 24927472
[TBL] [Abstract][Full Text] [Related]
10. Cancer Risk in Nodules Detected at Follow-Up Lung Cancer Screening CT.
Hammer MM; Byrne SC
AJR Am J Roentgenol; 2022 Apr; 218(4):634-641. PubMed ID: 34755524
[No Abstract] [Full Text] [Related]
11. Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.
Mendoza DP; Petranovic M; Som A; Wu MY; Park EY; Zhang EW; Archer JM; McDermott S; Khandekar M; Lanuti M; Gainor JF; Lennes IT; Shepard JO; Digumarthy SR
AJR Am J Roentgenol; 2022 Jul; 219(1):55-65. PubMed ID: 35080453
[No Abstract] [Full Text] [Related]
12. Receipt of Recommended Follow-up Care After a Positive Lung Cancer Screening Examination.
Rivera MP; Durham DD; Long JM; Perera P; Lane L; Lamb D; Metwally E; Henderson LM
JAMA Netw Open; 2022 Nov; 5(11):e2240403. PubMed ID: 36326760
[TBL] [Abstract][Full Text] [Related]
13. Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial.
Robbins HA; Katki HA; Cheung LC; Landy R; Berg CD
J Thorac Oncol; 2019 Sep; 14(9):1662-1665. PubMed ID: 31125735
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Risk Stratification Model of Pulmonary Ground-Glass Nodules Based on Complementary Lung-RADS 1.1 and Deep Learning Scores.
Meng Q; Li B; Gao P; Liu W; Zhou P; Ding J; Zhang J; Ge H
Front Public Health; 2022; 10():891306. PubMed ID: 35677762
[TBL] [Abstract][Full Text] [Related]
15. CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds.
Yankelevitz DF; Yip R; Smith JP; Liang M; Liu Y; Xu DM; Salvatore MM; Wolf AS; Flores RM; Henschke CI;
Radiology; 2015 Nov; 277(2):555-64. PubMed ID: 26101879
[TBL] [Abstract][Full Text] [Related]
16. Lung Cancer Deaths in the National Lung Screening Trial Attributed to Nonsolid Nodules.
Yip R; Yankelevitz DF; Hu M; Li K; Xu DM; Jirapatnakul A; Henschke CI
Radiology; 2016 Nov; 281(2):589-596. PubMed ID: 27378239
[TBL] [Abstract][Full Text] [Related]
17. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations.
Christensen J; Prosper AE; Wu CC; Chung J; Lee E; Elicker B; Hunsaker AR; Petranovic M; Sandler KL; Stiles B; Mazzone P; Yankelevitz D; Aberle D; Chiles C; Kazerooni E
Chest; 2024 Mar; 165(3):738-753. PubMed ID: 38300206
[TBL] [Abstract][Full Text] [Related]
18. CT Screening for Lung Cancer: Part-Solid Nodules in Baseline and Annual Repeat Rounds.
Henschke CI; Yip R; Smith JP; Wolf AS; Flores RM; Liang M; Salvatore MM; Liu Y; Xu DM; Yankelevitz DF;
AJR Am J Roentgenol; 2016 Dec; 207(6):1176-1184. PubMed ID: 27726410
[TBL] [Abstract][Full Text] [Related]
19. The diagnosis and management of multiple ground-glass nodules in the lung.
Li Q; Xiao T; Li J; Niu Y; Zhang G
Eur J Med Res; 2024 Jun; 29(1):305. PubMed ID: 38824558
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.
Sundaram V; Gould MK; Nair VS
Chest; 2021 Mar; 159(3):1273-1282. PubMed ID: 33393476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
